$818M Deal Lowballs Trius On Brink Of Drug Launch, Suit Says
A Trius Therapeutics Inc. shareholder brought a putative class action Friday aimed at stopping a buyout by Cubist Pharmaceuticals Inc. worth up to $818 million, calling the offer ill-timed and undervalued...To view the full article, register now.
Already a subscriber? Click here to view full article